title: Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.
abstract: Relapse is the main cause of therapeutic failure in follicular lymphoma (FL). We set out to evaluate the role of consolidation with Yttrium-90 ibritumomab tiuxetan in patients with intermediate- and high-risk FL after four cycles of CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) and two cycles of CHOP. Thirty patients were included. The overall response rate after consolidation therapy was 93%. Of the 18 patients who presented with a partial response after induction treatment, 11 had a complete response after consolidation treatment. The complete clinical response rate was 76.6%. The most important grade 3-4 toxicity was hematological, with 46% thrombopenia and 56% neutropenia. With a median follow-up of 26 months, the means for progression-free survival and overall survival were not reached. Our data support consolidation with Yttrium-90 ibritumomab tiuxetan as an effective treatment, which provides long progression-free and overall survival, in first line after a response to induction treatment in patients with intermediate- and high-risk FL.
authors.affiliation: Servicio de Oncología Médica, Hospital Puerta de Hierro , Madrid , Spain.
authors.forename: Mariano
authors.initials: M
authors.lastname: Provencio
authors.forename: Miguel Á
authors.initials: MÁ
authors.lastname: Cruz Mora
authors.forename: José
authors.initials: J
authors.lastname: Gómez-Codina
authors.forename: Cristina
authors.initials: C
authors.lastname: Quero Blanco
authors.forename: Marta
authors.initials: M
authors.lastname: Llanos
authors.forename: Francisco R
authors.initials: FR
authors.lastname: García-Arroyo
authors.forename: Luis
authors.initials: L
authors.lastname: de la Cruz
authors.forename: Josep
authors.initials: J
authors.lastname: Gumá Padró
authors.forename: Juan R
authors.initials: JR
authors.lastname: Delgado Pérez
authors.forename: Antonio
authors.initials: A
authors.lastname: Sánchez
authors.forename: Ruth
authors.initials: R
authors.lastname: Alvarez Cabellos
authors.forename: Antonio
authors.initials: A
authors.lastname: Rueda
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D060830:Consolidation Chemotherapy; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D012307:Risk Factors; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; C571759:R-CHOP protocol; D000069283:Rituximab; C422802:ibritumomab tiuxetan; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone